Shin Nippon Biomedical Laboratories, Ltd. Share Price OTC Markets
Equities
SBLOF
JP3379950003
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.97 USD | -.--% | -.--% | -.--% |
Sales 2024 | 26.45B 168M 13.22B | Sales 2025 * | 30.5B 194M 15.25B | Capitalization | 56.54B 360M 28.26B |
---|---|---|---|---|---|
Net income 2024 | 5.53B 35.2M 2.77B | Net income 2025 * | 4.3B 27.37M 2.15B | EV / Sales 2024 | 2.39 x |
Net Debt 2024 * | 19.51B 124M 9.75B | Net Debt 2025 * | 22.77B 145M 11.39B | EV / Sales 2025 * | 2.6 x |
P/E ratio 2024 |
11.4
x | P/E ratio 2025 * |
12.9
x | Employees | 1,341 |
Yield 2024 |
3.29% | Yield 2025 * |
3.76% | Free-Float | 48.8% |
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 31/08/81 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 30/04/02 |
Terumasa Hirai
CMP | Compliance Officer | - | 31/03/84 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ichiro Nagata
BRD | Director/Board Member | 38 | 31/03/17 |
Sales & Marketing | 64 | 31/10/02 | |
Ken Takanashi
COO | Chief Operating Officer | 60 | 30/11/02 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.06% | 58.06B | |
-5.77% | 40.53B | |
+37.49% | 38.99B | |
+13.21% | 26.7B | |
-12.01% | 26.56B | |
-21.52% | 18.98B | |
+1.24% | 12.17B | |
+23.06% | 12B | |
+26.32% | 11.92B |
- Stock Market
- Equities
- 2395 Stock
- SBLOF Stock